Indirect evidence suggests a link between factors produced during the inflammatory response and stunted growth. The demonstration of this link was provided by the observation that mice transgenic for the inflammatory cytokine interleukin-6 (IL-6), expressing high circulating levels of IL-6 since birth, show a marked decrease in growth rate leading to adult mice 50–70% the size of wild-type littermates. The growth defect is completely abolished by neutralization of IL-6. In these mice the production of GH is normal, while circulating levels of IGF-I are markedly decreased. Administration of IL-6 to wild-type mice results in a marked decrease in IGF-I levels. These observations show that in vivo high levels of IL-6 are associated with low levels of IGF-I. However, IL-6 does not directly affect IGF-I production both in vitro and in vivo. In contrast, markedly decreased levels of IGFBP-3 are present in the IL-6 transgenic mice and administration of IL-6 to wild-type mice results in a marked decrease in IGFBP-3 levels. In these mice the decrease in IGFBP-3 levels is associated with impaired formation of the 150 kD ternary complex, even in the presence of normally functional ALS. As a consequence, IL-6 transgenic mice show increased clearance of circulating IGF-I, suggesting that IL-6 decreases IGF-I levels by increased clearance. Proteolytic degradation of IGFBP-3 occurs in the IL-6 transgenic mice, suggesting that the decrease in IGFBP-3 could be at least in part due to proteolysis. The abnormalities of the IGF-I system observed in the IL-6 transgenic mice are similar to those found in patients with systemic juvenile idiopathic arthritis, one of the chronic inflammatory diseases characterized by stunted growth and prominent production of IL-6. The IL-6 transgenic mice represent a faithful animal model of the growth impairment associated with chronic inflammation and may therefore provide information relevant to the understanding and treatment of this complication of inflammatory diseases.

Keywords:
Cytokines, Arthritis, Animal model
1.
Kuhns JG, Swaim LT: Disturbances in growth in chronic arthritis in children. Am J Dis Child 1932;43:1180–1133.
2.
Ansell BM, Bywaters EGL: Growth in Still’s disease. Ann Rheum Dis 1956;15:295–319.
3.
Davies UM, Rooney M, Preece MA, Ansell BM, Woo P: Treatment of growth retardation in juvenile chronic arthritis with recombinant growth hormone. J Rheumatol 1994;21:153–158.
4.
Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO: Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993;105:681–691.
5.
Sproul A, Huang N: Growth patterns in children with cystic fibrosis. J Pediatr 1964;65:664–676.
6.
Fattori E, Lazzaro D, Musiani P, Modesti A, Alonzi T, Ciliberto G: IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increased in microglial cells but no neuronal damage. Eur J Neurosci 1995;7:2441–2449.
7.
De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E: Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643–650.
8.
De Benedetti F, Pignatti P, Vivarelli M, Meazza C, Ciliberto G, Savino R, Martini A: In vivo neutralization of human Il-6 (hIL-6) achieved by immunization with a hIL-6 receptor antagonist. J Immunol 2001;166:4334–4340.
9.
Milunsky A, Bray GA, Londono J, Loridan L: Insulin, glucose, growth hormone and free fatty acids. Determination in patients with cystic fibrosis. Am J Dis Child 1971;121:15–19.
10.
Laursen EM, Juul A, Lanng S, Hoiby N, Koch C, Muller J, Skakkebaek NE: Diminished concentrations of insulin-like growth factor-I in cystic fibrosis. Arch Dis Child 1995;72:494–497.
11.
Kirschner BS, Sutton MM: Somatomedin-C levels in growth impaired children and adolescent with chronic inflammatory bowel disease. Gastroenterology 1986;91:830–836.
12.
Tenore A, Berman WF, Parks JS, Bongiovanni AM: Basal and stimulated growth hormone concentrations in inflammatory bowel disease. J Clin Endocrinol Metab 1977;44:622–628.
13.
Braegger CP, Torresani T, Murch SH, Savage MO, Walker-Smith JA, MacDonald TT: Urinary growth hormone in growth impaired children with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:49–52.
14.
Thissen JP, Verniers J: Inhibition by interleukin-1β and tumor necrosis factor-α of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 1997;138:1078–1084.
15.
De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Barreca A, Martini A: Effect of interleukin-6 on IGFBP-3. A study in interleukin-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001;142:4818–4826.
16.
Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM, Preece MA, Woo PMM: Juvenile rheumatoid arthritis: Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 1997;40:332–340.
17.
Tsatsoulis A, Siamopoulou A, Petsoukis C, Challa A, Bairaktari E, Seferiadis K: Study of growth hormone secretion and action in growth-retarded children with juvenile chronic arthritis. Growth Horm IGF Res 1999;9:143–149.
18.
Beattie RM, Camacho-Hubner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO: Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn’s disease. Clin Endocrinol (Oxf) 1998;49:483–489.
19.
Taylor AM, Bush A, Thomson A, Oades PJ, Marchant JL, Bruce-Morgan C, Holly J, Ahmed L, Dunger DB: Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis. Arch Dis Child 1997;76:304–309.
20.
Bannerjee K, Croft NM, Babinska K, Edwards R, Camacho-Hubner C, Sanderson IR, Savage MO: Relationship of changes in IGF-I, IGFBP-3, ALS and leptin to inflammatory and nutritional markers during enteral feeding in children with Crohn’s disease (abstract). Program of the 39th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Brussels 2000, p 63.
21.
De Martino M, Galli L, Chiarelli F, Verrotti A, Rossi ME, Bindi G, Galluzzi F, Salti R, Vierucci A: Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection. Clin Immunol 2000;94:212–218.
22.
Johann-Liang R, O’Neill L, Cervia J, Haller I, Giunta Y, Licholai T, Noel GJ: Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. AIDS 2000;14:683–690.
23.
Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR: Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood 1999;93:3379–3390.
24.
Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ, Grogan T, Marquez LA, Janowska-Wieczorek A: Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin’s lymphomas. Blood 1999;94:2080–2089.
25.
Barille S, Collette M, Thabard W, Bleunven C, Bataille R, Amiot M: Soluble IL-6Rα upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells. Cytokine 2000;12:1426–1429.
26.
Lelbach A, Sharf JG, Ramadori G: Regulation of insulin-like growth factor I and of insulin-like growth factor binding protein-1, -3, and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J Hepatol 2001;35:558–567.
27.
Barreca A, Ketelslegers JM, Arvigo A, Minuto F, Thissen JP: Decreased acid-labile subunit levels by endotoxin in vivo and by interleukin-1β in vitro. Growth Horm IGF Res 1998;8:217–223.
28.
Davenport ML, Clemmons DR, Miles MV, Camacho-Hubner C, D’Ercole AJ, Underwood LE: Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology 1990;127:1278–1286.
29.
Thissen JP, Davenport ML, Pucilowska JB, Miles MV, Underwood LE: Increased serum clearance and degradation of 125I-labeled IGF-I in protein-restricted rats. Am J Physiol 1992;262:E406–E411.
30.
Cohen KL, Nissley SP: The serum half-life of somatomedin activity: Evidence for growth hormone dependence. Acta Endocrinol Copenh 1976;83:243–258.
31.
Zapf J, Hauri C, Waldvogel M, Froesch ER: Acute metabolic effects and half-life of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats. J Clin Invest 1986;77:1768–1775.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.